Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 2Unknown 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 42Lung Neoplasms 13Neoplasms 7Brain Neoplasms 6Pancreatic Neoplasms 3Neoplasm Metastasis 3NSCLC 3Gastrointestinal Neoplasms 2Esophageal Neoplasms 2Central Nervous System Neoplasms 2Breast Neoplasms 2Adenocarcinoma, Bronchiolo-Alveolar 2Adenocarcinoma of Lung 2Tongue Neoplasms 1Thoracic Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Respiratory Tract Diseases 1Relapsed Pediatric Solid Tumor 1Recurrence 1Precancerous Conditions 1Optic Nerve Glioma 1Non-squamous Non-small Cell Lung Cancer 1Metastatic Pancreatic Adenocarcinoma 1Medulloblastoma 1Lung Diseases 1Head and Neck Neoplasms 1Gliosarcoma 1Glioma 1Glioblastoma 1Familial ependymoma 1

Interventions

Verteporfin 1Radiotherapy 1Gelclair 1Etoposide 1Erlotinib Hydrochloride 1Amplified Fragment Length Polymorphism Analysis 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Familial ependymoma × Erlotinib Hydrochloride × Clear all
NCT00360854 2013-09-20

Erlotinib Alone or in Combination With Radiation Therapy in Treating Young Patients With Refractory or Relapsed Malignant Brain Tumors or Newly Diagnosed Brain Stem Glioma

National Cancer Institute (NCI)

Phase 1 Unknown
48 enrolled
CNS

Familial ependymoma, Astrocytoma, Medulloblastoma, Central Nervous System Neoplasms, Choroid Plexus Neoplasms, Optic Nerve Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡